Current trends in the treatment of HR+/HER2+ breast cancer

Charlene Kay*, Carlos Martinez-Perez, James Meehan, Mark Gray, Victoria Webber, J. Michael Dixon, Arran K. Turnbull

*Corresponding author for this work

Research output: Contribution to journalLiterature reviewpeer-review

Abstract / Description of output

Treatment for HR+/HER2+ patients has been debated, as some tumors within this luminal HER2+ subtype behave like luminal A cancers, whereas others behave like non-luminal HER2+ breast cancers. Recent research and clinical trials have revealed that a combination of hormone and targeted anti-HER2 approaches without chemotherapy provides long-term disease control for at least some HR+/HER2+ patients. Novel anti-HER2 therapies, including neratinib and trastuzumab emtansine, and new agents that are effective in HR+ cancers, including the next generation of oral selective estrogen receptor downregulators/degraders and CDK4/6 inhibitors such as palbociclib, are now being evaluated in combination. This review discusses current trials and results from previous studies that will provide the basis for current recommendations on how to treat newly diagnosed patients with HR+/HER2+ disease.

Original languageEnglish
Pages (from-to)1665-1681
Number of pages17
JournalFuture oncology
Issue number13
Early online date17 Mar 2021
Publication statusE-pub ahead of print - 17 Mar 2021

Keywords / Materials (for Non-textual outputs)

  • breast cancer
  • clinical trials
  • combination treatment
  • emerging therapeutics
  • HER2+
  • HR+/HER2+
  • luminal HER2
  • triple-positive breast cancer


Dive into the research topics of 'Current trends in the treatment of HR+/HER2+ breast cancer'. Together they form a unique fingerprint.

Cite this